Cell and Gene Therapy Manufacturing Services Global Market Opportunities and Strategies to 2033

This report describes and explains the cell and gene therapy manufacturing services market and covers 2018-2023, termed the historic period, and 2023-2028, 2033F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.

The global cell and gene therapy manufacturing services market reached a value of nearly $7 billion in 2023, having grown at a compound annual growth rate (CAGR) of 12.52% since 2018. The market is expected to grow from $7 billion in 2023 to $15.1 billion in 2028 at a rate of 16.71%. The market is then expected to grow at a CAGR of 17.70% from 2028 and reach $34.1 billion in 2033.

Growth in the historic period resulted from rising autoimmune diseases, rising prevalence of genetic disorders and rising demand for personalized medicine. Factors that negatively affected growth in the historic period were low healthcare access and high costs associated with the treatment.

Going forward, the growing number of cancer cases, growing healthcare expenditure, rising investments in research and development and increasing aging population will drive the growth. Factor that could hinder the growth of the cell and gene therapy manufacturing services market in the future include shortage of skilled workers.

The cell and gene therapy manufacturing services market are segmented by type into gene therapy and cell therapy. The gene therapy market was the largest segment of the cell and gene therapy manufacturing services market segmented by type, accounting for 61.8% or $4.3 billion of the total in 2023. Going forward, the gene therapy segment is expected to be the fastest growing segment in the cell and gene therapy manufacturing services market segmented by type, at a CAGR of 17.66% during 2023-2028.

The cell and gene therapy manufacturing services market are segmented by indication into central nervous system disorders, ophthalmology diseases, cardiovascular diseases, infectious diseases, orthopedic diseases, oncology diseases, metabolic diseases and other diseases. The oncology diseases market was the largest segment of the cell and gene therapy manufacturing services market segmented by indication, accounting for 27% or $1.9 billion of the total in 2023. Going forward, the oncology diseases segment is expected to be the fastest growing segment in the cell and gene therapy manufacturing services market segmented by indication, at a CAGR of 20.31% during 2023-2028.

The cell and gene therapy manufacturing services market is segmented by end-user into academic and research institutes, pharmaceutical and biotechnology companies and other end-users. The pharmaceutical and biotechnology market was the largest segment of the cell and gene therapy manufacturing services market segmented by end-user, accounting for 64.7% or $4.5 billion of the total in 2023. Going forward, the other end-users segment is expected to be the fastest growing segment in cell and gene therapy manufacturing services market segmented by end-user, at a CAGR of 17.98% during 2023-2028.

The cell and gene therapy manufacturing services market are segmented by application into commercial manufacturing and clinical manufacturing. The clinical manufacturing market was the largest segment of the cell and gene therapy manufacturing services market segmented by application, accounting for 66.4% or $4.6 billion of the total in 2023. Going forward, the commercial manufacturing segment is expected to be the fastest growing segment in the cell and gene therapy manufacturing services market segmented by application, at a CAGR of 18.56% during 2023-2028.

North America was the largest region in the cell and gene therapy manufacturing services market, accounting for 46.9% or $3.3 billion of the total in 2023. It was followed by Western Europe, Asia-Pacific and then the other regions. Going forward, the fastest-growing regions in the cell and gene therapy manufacturing services market will be Asia-Pacific and North America where growth will be at CAGRs of 18.11% and 17.37% respectively. These will be followed by Western Europe and Eastern Europe where the markets are expected to grow at CAGRs of 15.48% and 12.18% respectively.

The global cell and gene therapy manufacturing services market is highly concentrated, with a small number of large players dominating the market. The top ten competitors in the market made up 52.01% of the total market in 2022. Thermo Fisher Scientific, Inc. was the largest competitor with a 15.36% share of the market, followed by Merck KGaA with 11.18%, F. Hoffmann-La Roche Ltd with 9.09%, Charles River Laboratories International Inc. with 4.05%, Catalent Inc. with 3.05%, Lonza Group Ltd. with 2.50%, Boehringer Ingelheim with 2.17%, Fujifilm Holdings Corporation with 1.64%, Samsung Biologics with 1.55% and Novartis International AG with 1.43%

The top opportunities in the cell and gene therapy manufacturing services market segmented by type will arise in the gene therapy segment, which will gain $5.4 billion of global annual sales by 2028. The top opportunities in the cell and gene therapy manufacturing services market segmented by indication will arise in the oncology diseases segment, which will gain $2.9 billion of global annual sales by 2028. The top opportunities in the cell and gene therapy manufacturing services market segmented by application will arise in the clinical manufacturing segment, which will gain $5 billion of global annual sales by 2028. The top opportunities in the cell and gene therapy manufacturing services market segmented by end-user will arise in the pharmaceutical and biotechnology segment, which will gain $5.4 billion of global annual sales by 2028. The cell and gene therapy manufacturing services market size will gain the most in the USA at $3.5 billion.

Market-trend-based strategies for the cell and gene therapy manufacturing services market include strategic investments to expand manufacturing capacities, strategic collaborations for advancing cancer treatment production processes, development of next-generation CART therapies, enhancement in cell and gene therapy manufacturing with innovative technologies, innovative solutions driving efficiency in cell and gene therapy manufacturing.

Player-adopted strategies in the cell and gene therapy manufacturing services market include focus on optimizing cell therapy manufacturing process through the launch of new solutions, developing vector-based gene therapy applications through strategic partnerships and enhancing its business capabilities through new service launches.

To take advantage of the opportunities, the analyst recommends cell and gene therapy manufacturing companies to focus on advancing "off-the-shelf" allogeneic cell therapy, focus on implementing advanced technologies like the navigation platform, focus on integrated packaging solutions for cell and gene therapy, focus on gene therapy segment, expand in emerging markets, continue to focus on developed markets, focus on expanding in-house manufacturing capacity, focus on strategic collaborations for cancer treatment advancement, focus on competitive pricing strategies, participate in trade shows and events, continue to use B2B promotions, prioritize educational content and thought leadership, leverage digital marketing channels effectively and focus on other end-users segment for growth.